Salim S Abdool Karim

Summary

Affiliation: University of KwaZulu-Natal
Country: South Africa

Publications

  1. ncbi request reprint Durban 2000 to Toronto 2006: the evolving challenges in implementing AIDS treatment in Africa
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa CAPRISA, University of KwaZulu Natal and Columbia University, Congella 4013
    AIDS 20:N7-9. 2006
  2. ncbi request reprint Global epidemiology of HIV-AIDS
    Salim S Abdool Karim
    Centre for the AIDS Program of Research in South Africa CAPRISA, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Private Bag X7, Congella, 4013 Durban, South Africa
    Infect Dis Clin North Am 21:1-17, vii. 2007
  3. pmc Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection
    Ravesh Singh
    Doris Duke Medical Research Institute, University of KwaZulu Natal, Private Bag X7, Congella, Durban 4001, South Africa
    J Virol 85:208-16. 2011
  4. pmc Overview of microbicides for the prevention of human immunodeficiency virus
    Salim S Abdool Karim
    CAPRISA Centre of AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Private Bag X7, Congella 4013, Durban, South Africa
    Best Pract Res Clin Obstet Gynaecol 26:427-39. 2012
  5. pmc Conserved positive selection signals in gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection
    Gama P Bandawe
    Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa
    Virol J 5:141. 2008
  6. pmc Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial
    Quarraisha Abdool Karim
    Centre for the AIDS Programme of Research in South Africa CAPRISA, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa
    Trials 12:67. 2011
  7. ncbi request reprint Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care
    Salim S Abdool-Karim
    CAPRISA, University of KwaZulu Natal, South Africa
    AIDS 18:975-9. 2004
  8. pmc HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa CAPRISA, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa
    Lancet 374:921-33. 2009
  9. pmc Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa
    Quarraisha Abdool Karim
    Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa
    Int J Epidemiol 40:922-30. 2011
  10. pmc Integration of antiretroviral therapy with tuberculosis treatment
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
    N Engl J Med 365:1492-501. 2011

Detail Information

Publications46

  1. ncbi request reprint Durban 2000 to Toronto 2006: the evolving challenges in implementing AIDS treatment in Africa
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa CAPRISA, University of KwaZulu Natal and Columbia University, Congella 4013
    AIDS 20:N7-9. 2006
  2. ncbi request reprint Global epidemiology of HIV-AIDS
    Salim S Abdool Karim
    Centre for the AIDS Program of Research in South Africa CAPRISA, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Private Bag X7, Congella, 4013 Durban, South Africa
    Infect Dis Clin North Am 21:1-17, vii. 2007
    ..This article describes the modes of HIV transmission, geographic distribution of the evolving AIDS pandemic, and case studies of each of the three types of HIV epidemics, and presents global trends in AIDS and mortality...
  3. pmc Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection
    Ravesh Singh
    Doris Duke Medical Research Institute, University of KwaZulu Natal, Private Bag X7, Congella, Durban 4001, South Africa
    J Virol 85:208-16. 2011
    ..Collectively, these data suggest concordance between type 1 IFN and TRIM22 but not huTRIM5α expression in PBMCs and that TRIM22 likely acts as an antiviral effector in vivo...
  4. pmc Overview of microbicides for the prevention of human immunodeficiency virus
    Salim S Abdool Karim
    CAPRISA Centre of AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Private Bag X7, Congella 4013, Durban, South Africa
    Best Pract Res Clin Obstet Gynaecol 26:427-39. 2012
    ..Microbicides, which fill an important gap for women-controlled prevention methods, have the potential to alter the course of the HIV pandemic...
  5. pmc Conserved positive selection signals in gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection
    Gama P Bandawe
    Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa
    Virol J 5:141. 2008
    ..Besides being targeted by both the humoral and cellular arms of the immune system this protein mediates fusion between viral and target cell membranes and is likely to be a primary determinant of HIV transmissibility...
  6. pmc Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial
    Quarraisha Abdool Karim
    Centre for the AIDS Programme of Research in South Africa CAPRISA, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa
    Trials 12:67. 2011
    ..Microbicides could fill an important HIV prevention gap for sexually active women who are unable to successfully negotiate mutual monogamy or condom use...
  7. ncbi request reprint Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care
    Salim S Abdool-Karim
    CAPRISA, University of KwaZulu Natal, South Africa
    AIDS 18:975-9. 2004
  8. pmc HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa CAPRISA, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa
    Lancet 374:921-33. 2009
    ..Strong leadership, political will, social mobilisation, adequate human and financial resources, and sustainable development of health-care services are needed for successful implementation of these approaches...
  9. pmc Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa
    Quarraisha Abdool Karim
    Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa
    Int J Epidemiol 40:922-30. 2011
    ..In mature generalized human immunodeficiency virus (HIV) epidemics, as survival from accessing antiretroviral treatment (ART) increases, HIV prevalence data may be suboptimal and difficult to interpret without HIV incidence rates...
  10. pmc Integration of antiretroviral therapy with tuberculosis treatment
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
    N Engl J Med 365:1492-501. 2011
    ..We previously reported that integrating antiretroviral therapy (ART) with tuberculosis treatment reduces mortality. However, the timing for the initiation of ART during tuberculosis treatment remains unresolved...
  11. pmc HIV incidence in young girls in KwaZulu-Natal, South Africa--public health imperative for their inclusion in HIV biomedical intervention trials
    Quarraisha Abdool Karim
    Centre for the AIDS Programme of Research in South Africa CAPRISA, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Congella, Durban 4013, South Africa
    AIDS Behav 16:1870-6. 2012
    ..90). This study demonstrates that the inclusion of young girls between the ages of 14 and 17 years in longitudinal studies is feasible and their inclusion in clinical trials would maintain scientific integrity and power of the study...
  12. pmc Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
    Quarraisha Abdool Karim
    Centre for the AIDS Program of Research in South Africa CAPRISA, Durban 4013, South Africa
    Science 329:1168-74. 2010
    ..Tenofovir gel could potentially fill an important HIV prevention gap, especially for women unable to successfully negotiate mutual monogamy or condom use...
  13. pmc Neither microbial translocation nor TLR responsiveness are likely explanations for preexisting immune activation in women who subsequently acquired HIV in CAPRISA 004
    Vivek Naranbhai
    Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa
    J Acquir Immune Defic Syndr 63:294-8. 2013
    ..There was no difference between HIV acquirers and non-acquirers in the chemokine and cytokine responses of peripheral blood mononuclear cells stimulated with TLR2, 4, or 7/8 agonists. Further studies are required...
  14. pmc Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study
    Francois van Loggerenberg
    Centre for the AIDS Programme of Research in South Africa CAPRISA, University of KwaZulu Natal, Durban, South Africa
    PLoS ONE 3:e1954. 2008
    ..To describe the baseline demographic data, clinical characteristics and HIV-incidence rates of a cohort at high risk for HIV infection in South Africa as well as the challenges experienced in establishing and maintaining the cohort...
  15. pmc Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial
    Quarraisha Abdool Karim
    Centre for the AIDS Program of Research in South Africa CAPRISA, Durban, South Africa
    Contemp Clin Trials 32:333-8. 2011
    ..We describe our experience, remedial action taken, inter-organizational collaboration and lessons learnt following the identification of co-enrolled participants...
  16. pmc High rates of tuberculosis in patients accessing HAART in rural South Africa
    Kogieleum Naidoo
    Centre for the AIDS Programme of Research in South Africa CAPRISA, University of KwaZulu Natal, Durban, South Africa Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY and Oxford Department of Public Health, University of Oxford, Oxford, United Kingdom
    J Acquir Immune Defic Syndr 65:438-46. 2014
    ..The challenge of early tuberculosis (TB) infection among rural patients accessing highly active antiretroviral therapy (HAART) in a resource-limited setting with high HIV and TB burden has not been fully quantified...
  17. pmc Timing of initiation of antiretroviral drugs during tuberculosis therapy
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa
    N Engl J Med 362:697-706. 2010
    ..The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis therapy remains controversial...
  18. pmc The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis
    Tanuja N Gengiah
    Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa
    Eur J Clin Pharmacol 68:689-95. 2012
    ..Concomitant use of efavirenz (EFV) with the enzyme inducer rifampicin might be expected to increase EFV clearance. We investigated the influence of concomitant tuberculosis treatment on the plasma clearance of EFV...
  19. pmc HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services
    Ayesha B M Kharsany
    Centre for the AIDS Programme of Research in South Africa CAPRISA, 2nd Floor, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Private Bag 7, Congella, Durban 4013, South Africa
    BMC Public Health 12:231. 2012
    ..This study aimed at determining the HIV prevalence and explored the feasibility of HIV testing among high school learners...
  20. pmc TRIM5α and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment
    Ravesh Singh
    KwaZulu Natal Research Institute for Tuberculosis and HIV K RITH, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa
    J Virol 88:4291-303. 2014
    ....
  21. pmc Monitoring microbicide gel use with real-time notification of the container's opening events: results of the CAPRISA Wisebag study
    Tanuja N Gengiah
    Centre for the AIDS Programme of Research in South Africa CAPRISA, Doris Duke Medical Research Institute 2nd Floor, University of KwaZulu Natal, 719 Umbilo Road, Durban, South Africa
    AIDS Behav 18:833-40. 2014
    ..We recommend that the Wisebag be considered for larger scale and lengthier testing in microbicide trials...
  22. pmc Adherence in the CAPRISA 004 Tenofovir Gel Microbicide Trial
    Leila Essop Mansoor
    Centre for the AIDS Programme of Research in South Africa, 2nd Floor, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Private Bag X7, Congella, 4013, South Africa
    AIDS Behav 18:811-9. 2014
    ..Adherence support activities, which achieve levels of adherence similar to or better than those achieved by the CAPRISA 004 ASP, will be critical to the success of future microbicide trials. ..
  23. pmc When to start antiretroviral therapy during tuberculosis treatment?
    Kogieleum Naidoo
    Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa
    Curr Opin Infect Dis 26:35-42. 2013
    ..This review assesses the evidence for the timing of antiretroviral therapy (ART) initiation in patients coinfected with TB...
  24. ncbi request reprint Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial
    Vivek Naranbhai
    Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
    AIDS 26:1745-53. 2012
    ..To assess the role of natural killer (NK) cells in HIV acquisition...
  25. pmc A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection
    Tanuja N Gengiah
    Centre for the AIDS Program of Research in South Africa CAPRISA, University of KwaZulu Natal, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, Congella, Durban, South Africa
    Expert Opin Investig Drugs 21:695-715. 2012
    ..Oral and topical formulations of tenofovir have undergone preclinical and clinical testing to assess acceptability, safety and effectiveness in preventing HIV infection...
  26. pmc Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression
    Paradise Madlala
    HIV Pathogenesis Programme, University of KwaZulu Natal, Durban, South Africa
    AIDS 25:1711-9. 2011
    ..We investigated the influence of polymorphisms in PSIP1 on HIV-1 acquisition and disease progression in black South Africans...
  27. pmc Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial
    Sengeziwe Sibeko
    Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa
    Obstet Gynecol 118:895-904. 2011
    ....
  28. pmc Disclosure of Microbicide Gel Use to Sexual Partners: Influence on Adherence in the CAPRISA 004 Trial
    Kathryn Therese Mngadi
    Centre for the AIDS Program of Research in South Africa, Doris, Duke Medical Research Institute, University of KwaZulu Natal, Nelson R Mandela School of Medicine, 2nd Floor, Private Bag X7, Congella, 4013, South Africa
    AIDS Behav 18:849-54. 2014
    ..4 vs. 8.4 %; p = 0.01) and reported consistent condom use at baseline (32.9 vs. 20.9 %; p < 0.01). Partner disclosure needs to be better understood as a potential facilitator or barrier to microbicide adherence. ..
  29. pmc APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load
    Kavidha Reddy
    Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa
    AIDS 24:195-204. 2010
    ..We investigated the association of APOBEC3G mRNA levels and genetic variants on HIV-1 susceptibility, and early disease pathogenesis using viral load and CD4 T-cell counts as outcomes...
  30. pmc Uptake of provider-initiated HIV testing and counseling among women attending an urban sexually transmitted disease clinic in South Africa - missed opportunities for early diagnosis of HIV infection
    Ayesha B M Kharsany
    Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Private Bag 7 Congella, Durban 4013, South Africa
    AIDS Care 22:533-7. 2010
    ....
  31. pmc Health-related quality of life dynamics of HIV-positive South African women up to ART initiation: evidence from the CAPRISA 002 acute infection cohort study
    Andrew Tomita
    Centre for the AIDS Programme of Research in South Africa CAPRISA, University of KwaZulu Natal, Private Bag X7, Congella, 4013, South Africa
    AIDS Behav 18:1114-23. 2014
    ..While early ART delivery may be important for PWB and CF, factors such as education, contraception provision and good nutritional status should be promoted to maximize HRQoL in HIV positive individuals. ..
  32. pmc Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial
    Cheryl Baxter
    Centre for the AIDS Programme of Research in South Africa CAPRISA, University of KwaZulu Natal, Durban, South Africa Electronic address
    Antiviral Res 99:405-8. 2013
    ..The mean HBV DNA levels were similar at enrolment and exit in both study arms. Tenofovir gel, when used intermittently, was safe to use in women with HBV infection...
  33. doi request reprint Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women
    Jennifer E Balkus
    From the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Departments of Global Health and Biostatistics, University of Washington, Seattle, Washington Magee Womens Research Institute, Pittsburgh, Pennsylvania Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland Department of Obstetrics and Gynecology College of Health Science, University of Zimbabwe, Harare, Zimbabwe Center for Infectious Disease Research in Zambia, Lusaka, Zambia HIV Prevention Research Unit, South Africa Medical Research Council, Durban, South Africa Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina Centre for the AIDS Program of Research in South Africa, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Congella, South Africa and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York
    Sex Transm Dis 41:123-8. 2014
    ..The vaginal microbiota may play a role in mediating susceptibility to sexually transmitted infections, including Trichomonas vaginalis (TV)...
  34. pmc Anaemia in acute HIV-1 subtype C infection
    Koleka Mlisana
    Centre for the AIDS Programme of Research in South Africa CAPRISA, University of KwaZulu Natal, Durban, South Africa
    PLoS ONE 3:e1626. 2008
    ....
  35. ncbi request reprint Who infects whom? HIV-1 concordance and discordance among migrant and non-migrant couples in South Africa
    Mark N Lurie
    South African Medical Research Council, HIV Prevention and Vaccine Research Unit, Durban, South Africa
    AIDS 17:2245-52. 2003
    ..To measure HIV-1 discordance among migrant and non-migrant men and their rural partners, and to estimate the relative risk of infection from inside versus outside primary relationships...
  36. pmc Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa CAPRISA, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Congella, South Africa
    AIDS 25:957-66. 2011
    ..To determine the safety and effectiveness of BufferGel and 0.5% PRO2000 microbicide gels for the prevention of male-to-female HIV transmission...
  37. ncbi request reprint The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners
    Mark N Lurie
    South African Medical Research Council, HIV Prevention and Vaccine Research Unit, Durban, South Africa
    Sex Transm Dis 30:149-56. 2003
    ..To investigate the association between migration and HIV infection among migrant and nonmigrant men and their rural partners...
  38. pmc Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa
    Jerome Amir Singh
    Centre for AIDS Programme of Research in South Africa, Congella, South Africa
    PLoS Med 3:e180. 2006
  39. pmc Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women
    Veron Ramsuran
    HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa
    Clin Infect Dis 52:1248-56. 2011
    ..The influence of pre-seroconversion levels of peripheral blood cell counts (PBCs) on the risk of acquiring human immunodeficiency virus (HIV)-1 infection among Africans is unknown...
  40. ncbi request reprint Medical education after the first decade of democracy in South Africa
    Salim S Abdool Karim
    CAPRISA, University of KwaZulu Natal, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban 4013, South Africa
    Lancet 363:1395. 2004
  41. ncbi request reprint Dual HIV-1 infection associated with rapid disease progression
    Geoffrey S Gottlieb
    Department of Microbiology, School of Medicine, University of Washington, Seattle, WA 98195 8070, USA
    Lancet 363:619-22. 2004
    ..4 and <3.1 years, respectively). Our findings should prompt larger studies to assess the effect of dual infection at the population level...
  42. ncbi request reprint HIV incidence estimates are key to understanding the changing HIV epidemic in South Africa
    Salim S Abdool Karim
    S Afr Med J 97:190. 2007
  43. ncbi request reprint Increasing burden of pulmonary tuberculosis in young women
    Ayesha B M Kharsany
    S Afr Med J 96:524-5. 2006
  44. ncbi request reprint Utilizing nucleic acid amplification to identify acute HIV infection
    Salim S Abdool Karim
    AIDS 21:653-5. 2007
  45. ncbi request reprint Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial
    Lut Van Damme
    Institute of Tropical Medicine, Antwerp, Belgium
    Lancet 360:971-7. 2002
    ..Results of studies of its effectiveness in prevention of HIV-1 infection in women have been inconclusive. We aimed to assess effectiveness of this vaginal gel...